Personalized Cancer Vaccine Summit

Temas de la conferencia
With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical point to demonstrate safe and efficacious results that will offer a real hope for every patient with a cure for cancer.

Organizador profesional (PCO)
Hanson Wade

Observaciones
URL:
Brochure: https://go.evvnt.com/2558274-3?pid=4832

Speakers: Agnete Fredriksen, Chief Scientific Officer, Nykode Therapeutics, Charles Link, Chief Medical Officer, Syncromune, David Berd, Chief Medical Officer, Biovaxys, and more

https://go.evvnt.com/2558274-2?pid=4832

Ms. Isabel Weir